Aussie Chemgenex Licenses Leukemia Drug To Support U.S. Push
This article was originally published in PharmAsia News
Executive Summary
Australia's Chemgenex has signed a deal with U.S.-based Hospira that could be worth $119.4 million to the Australian firm by the time it runs its course